Genprex to Participate in 2024 BIO Europe Conference [Yahoo! Finance]
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
on developing life-changing therapies for patients with cancer and diabetes, today announced its participation in the upcoming BIO Europe Conference, taking place Nov. 4-6, 2024 in Stockholm, Sweden and taking place virtually Nov. 12-13, 2024 Attending in-person will be Genprex's Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, Esq. In addition, the Company's President and Chief Executive Officer, Ryan Confer , and Chief Medical Officer, Mark Berger , MD, will be participating virtually. Throughout the duration of the conference, Genprex will be available to conduct one-on-one meetings with industry and investor groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting Genprex management during the conference, please request a meeting through the conference portal or reach out to Investor Relations at investors@genprex.com About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerPR Newswire
- Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerPR Newswire
- Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingPR Newswire
GNPX
Sec Filings
- 12/20/24 - Form 424B5
- 12/16/24 - Form 8-K
- 12/6/24 - Form 4
- GNPX's page on the SEC website